[{"NetIncomeLoss_1_Q2_USD":-52405000.0,"DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax_0_Q2_USD":0.0,"InterestPaidNet_2_Q2_USD":22490000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":8000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":149463000.0,"StockIssuedDuringPeriodValueNewIssues_1_Q2_USD":108180000.0,"StockIssuedDuringPeriodValueNewIssues_0_Q2_USD":115600000.0,"StockIssuedDuringPeriodValueNewIssues_2_Q2_USD":108180000.0,"AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_1_Q2_USD":727000.0,"AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_2_Q2_USD":6320000.0,"AssetsCurrent_0_Q2_USD":333180000.0,"LongTermDebt_0_Q2_USD":609509000.0,"OtherNoncashIncomeExpense_2_Q2_USD":168000.0,"CommitmentsAndContingencies_0_Q2_USD":null,"PaymentsToAcquireAvailableForSaleSecuritiesDebt_2_Q2_USD":40014000.0,"SellingGeneralAndAdministrativeExpense_2_Q2_USD":56481000.0,"SellingGeneralAndAdministrativeExpense_1_Q2_USD":25931000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":14983000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q2_shares":12904000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_2_Q2_USD":5000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q2_USD":2000.0,"IncomeTaxesPaidNet_2_Q2_USD":12000.0,"ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2_Q2_USD":191400000.0,"CommonStockSharesIssued_0_Q2_shares":73470000.0,"AvailableForSaleSecuritiesDebtSecurities_0_Q2_USD":235497000.0,"Assets_0_Q2_USD":429251000.0,"ShareBasedCompensation_2_Q2_USD":30773000.0,"IncreaseDecreaseInPrepaidExpensesOther_2_Q2_USD":1993000.0,"DueFromRelatedPartiesCurrent_0_Q2_USD":27741000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":65669000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":65085000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":51093000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":65085000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":65669000.0,"IncreaseDecreaseInAccruedLiabilities_2_Q2_USD":-33125000.0,"ProceedsFromStockPlans_2_Q2_USD":2862000.0,"OtherNonoperatingIncomeExpense_2_Q2_USD":937000.0,"OtherNonoperatingIncomeExpense_1_Q2_USD":1171000.0,"IncomeTaxExpenseBenefit_2_Q2_USD":7000.0,"IncomeTaxExpenseBenefit_1_Q2_USD":-220000.0,"CommonStockValue_0_Q2_USD":1000.0,"InterestPayableCurrent_0_Q2_USD":3900000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":93997000.0,"OtherDepreciationAndAmortization_2_Q2_USD":2926000.0,"StockIssuedDuringPeriodSharesNewIssues_0_Q2_shares":7705000.0,"RestrictedCash_0_Q2_USD":833000.0,"OtherPrepaidExpenseCurrent_0_Q2_USD":12353000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-132123000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-52414000.0,"IncreaseDecreaseInAccountsPayable_2_Q2_USD":4026000.0,"OtherAssetsNoncurrent_0_Q2_USD":1325000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":204949000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":57768000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q2_USD":-9000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2_Q2_USD":-39000.0,"EquityMethodInvestments_0_Q2_USD":35822000.0,"PreferredStockSharesOutstanding_0_Q2_shares":0.0,"ConvertibleLongTermNotesPayable_0_Q2_USD":227499000.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":41508000.0,"PreferredStockParOrStatedValuePerShare_0_Q2_USD":0.0,"ProceedsFromIssuanceOfCommonStock_2_Q2_USD":108180000.0,"RepaymentsOfNotesPayable_2_Q2_USD":10730000.0,"IncomeLossFromEquityMethodInvestments_1_Q2_USD":21926000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q2_USD":8000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_Q2_USD":-132077000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q2_USD":-52625000.0,"DeferredTaxLiabilityNotRecognizedAmountOfUnrecognizedDeferredTaxLiabilityUndistributedEarningsOfForeignSubsidiaries_0_Q2_USD":0.0,"PaymentsRelatedToTaxWithholdingForShareBasedCompensation_2_Q2_USD":6320000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2_Q2_USD":30773000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q2_USD":14941000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-119978000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":65199000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":65669000.0,"PaymentsToAcquireProductiveAssets_2_Q2_USD":1923000.0,"LiabilitiesCurrent_0_Q2_USD":67127000.0,"AccountsPayableCurrent_0_Q2_USD":10702000.0,"InterestExpense_2_Q2_USD":23485000.0,"InterestExpense_1_Q2_USD":11612000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q2_USD":205782000.0,"ProceedsFromStockOptionsExercised_2_Q2_USD":5000.0,"OtherAccruedLiabilitiesCurrent_0_Q2_USD":1496000.0,"FinanceLeaseRightOfUseAssetAmortization_2_Q2_USD":1752000.0,"IncreaseDecreaseInOtherOperatingAssets_2_Q2_USD":-997000.0,"AdditionalPaidInCapital_0_Q2_USD":1358318000.0,"StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_2_Q2_USD":2862000.0,"StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1_Q2_USD":2862000.0,"PreferredStockSharesIssued_0_Q2_shares":0.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":16583000.0,"NetIncomeLoss_2_Q2_USD":-132084000.0,"IncomeLossFromEquityMethodInvestments_2_Q2_USD":38473000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":118692000.0,"RestrictedCashNoncurrent_0_Q2_USD":833000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":123482000.0,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.0,"FairValueAssetsLevel1ToLevel2TransfersAmount_0_Q2_USD":0.0,"CommonStockSharesAuthorized_0_Q2_shares":200000000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":27171000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":12914000.0,"OperatingIncomeLoss_2_Q2_USD":-148002000.0,"OperatingIncomeLoss_1_Q2_USD":-64110000.0,"AvailableForSaleSecuritiesDebtSecuritiesCurrent_0_Q2_USD":60004000.0,"IncreaseDecreaseInInterestPayableNet_2_Q2_USD":-74000.0,"ContractWithCustomerLiabilityCurrent_0_Q2_USD":5690000.0,"PreferredStockValue_0_Q2_USD":null,"LiabilitiesAndStockholdersEquity_0_Q2_USD":429251000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q2_USD":14635000.0,"PreferredStockSharesAuthorized_0_Q2_shares":230000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":30773.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":14941000.0,"SharePrice_0_Q2_USD":15.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":1037000.0,"OperatingExpenses_2_Q2_USD":175173000.0,"OperatingExpenses_1_Q2_USD":77024000.0,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-0.8,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-2.03,"OtherLiabilitiesNoncurrent_0_Q2_USD":1833000.0,"StockholdersEquity_0_Q2_USD":-300374000.0,"ContractWithCustomerLiabilityNoncurrent_0_Q2_USD":329000.0,"AvailableForSaleDebtSecuritiesAmortizedCostBasis_0_Q2_USD":235489000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-1658701000.0,"CommonStockSharesOutstanding_0_Q2_shares":73470000.0,"IncreaseDecreaseInContractWithCustomerLiability_2_Q2_USD":-5852000.0,"Ticker":"TBPH","CIK":"1583107","name":"THERAVANCE BIOPHARMA, INC.","OfficialName":"Theravance Biopharma Inc. Ordinary Shares","form":"10-Q","period":"20210630","fy":"2021.0","fp":"Q2","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"688048421.0","Country":"Cayman Islands","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20210805"}]